We are distinguished by our skilled and motivated team of employees with highly specialized scientific backgrounds, which reflects our focus on innovative technologies.
Emerging from the Institute of Cell Culture Technology at Bielefeld University in 2009, Xell AG (formerly TeutoCell AG) has grown to become a privately financed, internationally orientated biotech company with a strong focus on innovation and expertise. With more than 20 years of hands-on experience in cell culture, Xell AG has drawn from its academic and technological expertise to become a key partner for the design and distribution of cell culture solutions. From launching its first commercial products for CHO and hybridoma cell lines in 2010, Xell AG has continuously developed new products and tools for mammalian cell cultivation, benefiting from strong partnerships in industry and academia.
Moving to a new facility in 2015, Xell AG now has additional capacities and has expanded its portfolio of innovative off-the-shelf media to encompass a wider range of cell lines like HEK, as well as applications like enhanced transfection, transient expression and virus production.
Mutual benefits through long-standing relationships.
With years of experience we have gained a reputation as a reliable and dedicated partner for the scientific community and biotechnology industry. Among others, we are happy to call Sanofi and Boehringer Ingelheim long-term clients.
We collaborate with companies and universities around the globe to broaden our portfolio and create new possibilities to support your ideas.
ACYTE Biotech Pty Ltd is an Australian- based biotech company specializing in proprietary technologies in mammalian cell engineering and cell culture. ACYTE aims to reduce bottlenecks in early stage biopharmaceutical development by providing a suite of SuperCHO® technologies to streamline the path from discovery to clinic. Two key technologies include:
ACYTE has a wealth of experience in stable cell line development combining its proprietary suspension adapted cell line, XL-99, with versatile, highly stringent expression vectors and high throughput clone selection platform. The system is ideal for generating cell lines in a rapid time frame which are scalable for clinical and commercial applications.(Information provided by our partners)
Xell has partnered with ACYTE to combine fast stable cell line generation with highly efficient medium and feed solutions, tailored for the developed cells.
Visit ACYTE Biotech for more information on cell line development and contact details.
BIBITEC Gesellschaft für Prozessentwicklung mbH is specialized in the production and purification of proteins (e.g. hormones, mAbs) derived from mammalian cell cultures.One major achievement was an erythropoietin (EPO) project that involved the process development and the GMP- compliant production of an EPO biosimilar for use in phase III clinical trials.The entire production and purification process was successfully transferred for large-scale production leading to one of the first successful approvals of a biosimilar in Europe.
In 2012 BIBITEC became part of Nordmark Arzneimittel GmbH & Co. KG, Uetersen. In cooperation with Nordmark and other validated partners BIBITEC provides all activities from “gene to product” including cell line and process development, GMP production, fill-and-finish and analytics.(Information provided by our partners)
Biofidus is a newly founded bioanalytical company located in Bielefeld, Germany. Its services include a wide variety of bioanalytical methods such as spectroscopic, chromatographic or mass spectrometric assays focused on characterization of proteins as well as small molecules.
The experts at Biofidus represent over 40 years of bioanalytical experience, allowing it to find the solution to your bioanalytical project.
Biofidus can help solve your toughest challenges from routine high throughput analysis to development of novel client- specific assays.(Information provided by our partners)
InVivo is an ISO 9001 certified contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins for research, diagnostic and pre-clinical use. Since 1998 InVivo provides cost-effective outsourcing solutions for a large number of satisfied clients.
A wide range of different hybridomas have been cultivated in InVivo’s proprietary serum-free media ISF1. Production under serum-free conditions enables high productivity without the drawbacks of serum-containing processes, e.g. contamination with bovine IgGs. High cell density fermentation using different cell retention systems yields up to 500 mg antibody per liter per day. After a one step purification using recombinant protein- A/G our monoclonal antibodies are of highest purity.
Furthermore InVivo offers the complete range of modern recombinant protein expression techniques. Starting from synthetic cDNAs the protein can be expressed in bacteria, insect or mammalian cell lines. To meet customer ́s needs for mammalian derived proteins on short order we offer transient transfection using HEK- and CHO- cells. This fast and productive alternative is often favored over stable cell line development.(Information provided by our partners)
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Their innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, Miltenyi’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture.
Their 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has more than 1,500 employees in 25 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.(Information provided by our partners)
trenzyme GmbH is a privately owned German Contract Research Organization (CRO) offering a wide range of highly customized services in cell line development and recombinant protein production.
Since 2000, trenzyme has been a valued research partner of national and international clients, ranging from academia and small biotechs to big pharmaceutical companies. Their highly skilled scientific experts provide a one-stop-shop from cloning to development of stable assay cell lines or GMP-compliant production cell lines. Both cell line services rely on powerful and well-established platforms: their proprietary ExoIN technology (stable assay cell line generation) and the CHOvolutionTM platform (GMP-compliant production cell line development).
Whether your needs lie in the development of assay cell lines, production cell lines or in recombinant protein production, trenzyme’s team is continuously developing new and comprehensive solutions to provide reliable, up-to-date support for your individual and demanding projects. As full service provider for the life science industry, they are dedicated to delivering the ideal solution for their clients at highest quality standards and maximum efficiency, saving your valuable research time and accelerating your innovation.(Information provided by our partners)
With our international network of partners in academia, we continuously work on innovative ideas to advance our industry.
By synergistic cooperation with these research teams, each experts in their field, we can transfer latest insights into practice.